Toral I, Ciliv G, Gürsel B, Ozdem C
Department of Otolaryngology, Numune Hospital, Ankara, Turkey.
Eur Arch Otorhinolaryngol. 1990;247(4):244-6. doi: 10.1007/BF00178995.
Specific androgen receptors were assayed from the cytosol fraction of laryngeal carcinomas from 15 male patients. Specimens also included the non-malignant laryngeal tissues from 3 of these patients. A specific radioligand was used and involved (3H) dihydrotestosterone incubation and a dextran-coated charcoal technique. Twelve of the laryngeal carcinomas showed detectable levels of high affinity but limited capacity androgen receptors. The number of binding sites varied from zero to 23.3 fmol/mg cytosol protein, with the dissociation coefficient (Kd) ranging from 0.46 to 1.85 x 10(-9) M. Androgen receptors were also found in all three non-malignant laryngeal tissues. Binding sites for these latter androgen receptors were 4.09 to 8.16 fmol/mg cytosol protein, with a Kd of 0.81 to 0.35 x 10(-9) M. Although further studies are necessary, the presence of androgen receptors in laryngeal carcinomas suggests that antiandrogen therapy might be used in the future for treating such disease.
从15名男性患者的喉癌胞质溶胶组分中检测特异性雄激素受体。标本还包括其中3名患者的非恶性喉组织。使用了一种特异性放射性配体，包括（3H）二氢睾酮孵育和葡聚糖包被活性炭技术。12例喉癌显示出可检测到的高亲和力但有限容量的雄激素受体水平。结合位点数量从零到23.3 fmol/mg胞质溶胶蛋白不等，解离系数（Kd）范围为0.46至1.85×10（-9）M。在所有三个非恶性喉组织中也发现了雄激素受体。这些后一种雄激素受体的结合位点为4.09至8.16 fmol/mg胞质溶胶蛋白，Kd为0.81至0.35×10（-9）M。尽管需要进一步研究，但喉癌中雄激素受体的存在表明抗雄激素治疗未来可能用于治疗此类疾病。
